Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Gets Medicare Coverage for mets2 Assay; Stock Soars

NEW YORK (GenomeWeb News) – Rosetta Genomics today said that Novitas, a designated Medicare contractor, has informed the firm that it plans to cover its miRview mets2 assay for all Medicare beneficiaries.

Rosetta's shares climbed as high as $7.84 in Wednesday trade on the Nasdaq, before closing at $4.99, up 208 percent.

The miRview mets2 test identifies tumor of origin in primary and metastatic cancer including cancer of unknown or uncertain primary.

"This is a major commercial achievement for Rosetta Genomics as Medicare coverage is a critical step toward widespread commercial adoption and payment for our lead diagnostic assay, miRview mets2, and enables access to this clinically valuable test to Medicare patients," Rosetta Genomics President and CEO Kenneth Berlin said in a statement. "This decision is important not only because Medicare is the largest US payor, covering a large percentage of the patients for whom miRview mets2 has been ordered historically and would be expected to be ordered in the future, but also because private payors often look to Medicare's decisions when setting their own reimbursement policies."

The daramtic jump in Rosetta's stock follows a one-for-fifteen reverse stock split that took place earlier this week. At the time, the firm's shares were trading at $.14. It also has been under threat of delisting from the Nasdaq for failing to satisfy two listing requirements: the $1 minimum bid rule and having $2.5 million in stockholders equity.

The Scan

Wolf Howl Responses Offer Look at Vocal Behavior-Related Selection in Dogs

In dozens of domestic dogs listening to wolf vocalizations, researchers in Communication Biology see responses varying with age, sex, reproductive status, and a breed's evolutionary distance from wolves.

Facial Imaging-Based Genetic Diagnoses Appears to Get Boost With Three-Dimensional Approach

With data for more than 1,900 individuals affected by a range of genetic conditions, researchers compared facial phenotype-based diagnoses informed by 2D or 3D images in the European Journal of Human Genetics.

Survey Suggests Multigene Cancer Panel VUS Reporting May Vary Across Genetic Counselors

Investigators surveyed dozens of genetic counselors working in clinical or laboratory settings, uncovering attitudes around VUS reporting after multigene cancer panel testing in the Journal of Genetic Counseling.

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.